Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

On September 3, 2024 Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26 th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel (Press release, Indaptus Therapeutics, SEP 3, 2024, View Source;qmodStoryID=5871576807142026 [SID1234646315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Date: September 9, 2024
Time: Available on-demand starting at 7:00 AM Eastern Time
Webcast Link: View Source
A live webcast of the presentation can be accessed on the investor relations section of the Indaptus website. A replay of the webcast will be archived and available following the event for approximately 90 days.
View Source

Mr. Meckler will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:

View Source

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

On September 3, 2024 HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, reported that it has filed an investigational new drug (IND) application with China’s National Medical Products Administration to conduct a clinical trial of HF50, a first-of-its-kind immunoliposome that directs T cells to attack solid tumors and enhances the anticancer activity with an immune modulator (Press release, HighField Biopharmaceuticals, SEP 3, 2024, View Source [SID1234646332]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HF50 is a lipid bilayer system with two different antibodies attached; the first bind to T cells and the second bind to tumor cells, engaging the T cells to destroy the cancer. This unique lipid structure is called a T cell Redirecting Antibody Fragment-anchored Liposome, or TRAFsome. It also carries a payload of Resiquimod, a small molecule compound that modulates T cell response, enhancing anti-tumor activity.

"Our TRAFsomes attach to receptors on the surface of T cells, externally coating the immune cells with tumor targeting antibodies, converting the T cells into an army of cancer destroyers," said Yuhong Xu, Ph.D., HighField’s CEO and Scientific Founder. "HF50 also represents the first systemic use of Resiquimod, and data show that stimulating the immune T cells in this manner greatly enhances the anti-tumor activity."

As a T cell engager of cancer, HF50 has multiple advantages over others such as bispecific antibodies and CAR T therapy, Dr. Xu added. "Bispecifics have very limited antibody conjugation schemes," she explained, "limiting their efficacy in solid tumors. As for CAR T, the goal is to produce T cells expressing anti-tumor antibodies on their outer membrane. HF50 achieves this goal without the complex and expensive processing inherent in CAR T therapies."

In addition, Dr. Xu observed, most existing T cell engagers have a higher risk of toxicity than HF50. "Our product has a liposome-based in vivo action process," she said, "which is less distributed in normal tissues, but can concentrate in solid tumors through the enhanced permeability and retention effect."

In preclinical studies, HF50 has shown to be a highly effective anti-cancer agent in both in vitro and in vivo. The data demonstrate that it processes a novel cell bridging function between T cells and tumor cells, with the capability of activating immune cells. HF50 effectively stimulates T cell activation and displays significant efficacy in humanized tumor-bearing mice models. Pharmacokinetic research also confirms HF50 successfully maintains drug levels in the bloodstream, and improves drug accumulation within tumor tissues.

Step Pharma announces first patient dosed in a phase 1 trial of dencatistat for patients with solid tumours

On September 3, 2024 Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, reported that the first patient has been dosed at Next Oncology, San Antonio, TX USA, with its lead asset dencatistat (STP938) in a clinical trial for patients with solid tumours (Press release, Step Pharma, SEP 3, 2024, View Source [SID1234646348]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This open label trial is evaluating the safety, tolerability and pharmacokinetics of dencatistat, a first-in-class, highly selective, orally bioavailable CTPS1 inhibitor. The trial consists of two parts: a phase 1a dose escalation recruiting patients with solid tumours, followed by a phase 1b expansion cohort specifically for patients with CTPS2 null ovarian cancer, planned to start in Q1 2025.

Approximately 325,000 women worldwide are diagnosed with ovarian cancer each year. 15-20% of ovarian cancers harbour a deletion of the gene encoding CTPS2. Selecting patients whose tumours have deleted CTPS2 represents a precision oncology approach that is expected to maximise the therapeutic potential of dencatistat. The trial is recruiting patients with advanced cancer who have no other treatment options available.

Andrew Parker, Chief Executive Officer of Step Pharma, commented:

"The start of our first clinical trial of dencatistat for solid tumours marks a significant milestone in our ‘pipeline in a product’ strategy. Dencatistat, our first-in-class CTPS1 inhibitor, is now expanding from blood cancers to solid tumours, demonstrating its versatility. With a substantial number of ovarian cancer patients potentially harbouring CTPS2 deletions, and similar deletions observed in other cancer types, we are excited about the potential of dencatistat as a tumour-agnostic targeted treatment."

Furthermore, the Company announces that the Clinical Trial Application for the phase 1 trial of dencatistat in patients with solid tumours has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). This approval, along with the previously cleared Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), announced in June 2024, enables the Company to progress dencatistat into clinical trials in both the UK and the US.

The start of this solid tumour trial follows the ongoing phase 1/2 trial of dencatistat for adult patients with relapsed/refractory T or B cell lymphoma, which commenced in October 2022.

Step Pharma is pioneering a novel class of oral drugs that specifically inhibit nucleotide synthesis and the enzyme CTPS1 in particular, which was originally identified as an essential gene for lymphocyte proliferation. By targeting CTPS1, Step Pharma has unlocked the ability to selectively target the de novo pyrimidine synthesis pathway in cancer cells. This groundbreaking approach is predicted to enable the highly selective treatment of both blood cancers and solid tumours.

Further details of the planned Phase 1 trial can be found on clinicaltrials.gov under the identifier NCT06297525.

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

On September 3, 2024 BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, reported that it will have an oral presentation on the final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from Dublin-3 phase 3 study in EGFR wild-type 2L/3L non-small cell lung cancer (NSCLC) at the 2024 World Conference on Lung Cancer, on September 9, 2024 in San Diego, CA, and two poster presentations on Dublin-3 study safety outcome and 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) in 2L/3L NSCLC who failed PD-1/PD-L1 inhibitors at European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024, on September 14, 2024 in Barcelona, Spain (Press release, BeyondSpring Pharmaceuticals, SEP 3, 2024, View Source;utm_medium=rss&utm_campaign=beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-two-poster-presentations-during-esmo-congress-2024-showcasing-its-lead-anti-cancer-asset-plinabulin [SID1234646282]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

​​Presentation details are as follows:

2024 World Conference on Lung Cancer

Oral (OA08.04): Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial

Presenter: Trevor M. Feinstein, Principal investigator for Dublin-3 study, Piedmont Cancer Institute, Atlanta, GA, USA
Presentation Time: Monday, September 9, 2024, at 10:57AM to 11:07AM PDT
Session: OA08. The New Generation of Cytotoxics
ESMO Congress 2024

Poster (1358P): Plinabulin/Docetaxel Versus Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial

Presenter: Trevor M. Feinstein
Presentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CEST
Location: Hall 3, Av. Joan Carles I, 64
08908 L’hospitalet de Llobregat

Barcelona, Spain

Session: NSCLC, metastatic
Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization

Presenter: Yan Xu, Investigator, Peking Union Medical College Hospital, Beijing, China
Presentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CEST
Location: Hall 3, Av. Joan Carles I, 64
08908 L’hospitalet de Llobregat

Barcelona, Spain

Session: NSCLC, metastatic

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ON September 3, 2024 Moleculin Biotech, Inc., a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, reported that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY (Press release, Moleculin, SEP 3, 2024, https://moleculin.com/moleculin-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference/ [SID1234646299]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (moleculin.com). The webcast replay will be archived for 90 days following the event.